Adverse reactions and treatment measures of advanced solid tumors treated with antibody-drug conjugates / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 220-224, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-930069
ABSTRACT
Novel antibody-drug conjugates (ADCs) are a hot spot in the research and development of new drugs for advanced solid tumors. ADCs have achieved significant efficacy in the treatment of advanced breast cancer, urothelial carcinoma, gastric cancer and other solid tumors, but their adverse reactions such as ocular toxicity, pulmonary toxicity, hematological toxicity, and liver toxicity cannot be ignored, and it is crucial to effectively deal with the adverse reactions of ADCs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS